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Abstract
Background: Blockade of the renin-angiotensin system (RAS) reduces the incidence of type 2 diabetes mellitus. In rodents, it
has been demonstrated that RAS blockade improved adipose tissue (AT) function and glucose homeostasis. However, the
effects of long-term RAS blockade on AT function have not been investigated in humans. Therefore, we examined whether
26-wks treatment with the angiotensin II type 1 receptor blocker valsartan affects AT function in humans with impaired
glucose metabolism (IGM).
Methodology/Principal Findings: We performed a randomized, double-blind, placebo-controlled parallel-group study, in
which 38 subjects with IGM were treated with valsartan (VAL, 320 mg/d) or placebo (PLB) for 26 weeks. Before and after
treatment, an abdominal subcutaneous AT biopsy was collected for measurement of adipocyte size and AT gene/protein
expression of angiogenesis/capillarization, adipogenesis, lipolytic and inflammatory cell markers. Furthermore, we evaluated
fasting and postprandial AT blood flow (ATBF) (
133Xe wash-out), systemic inflammation and insulin sensitivity
(hyperinsulinemic-euglycemic clamp). VAL treatment markedly reduced adipocyte size (P,0.001), with a shift toward a
higher proportion of small adipocytes. In addition, fasting (P=0.043) and postprandial ATBF (P=0.049) were increased,
whereas gene expression of angiogenesis/capillarization, adipogenesis and macrophage infiltration markers in AT was
significantly decreased after VAL compared with PLB treatment. Interestingly, the change in adipocyte size was associated
with alterations in insulin sensitivity and reduced AT gene expression of macrophage infiltration markers. VAL did not alter
plasma monocyte-chemoattractant protein (MCP)-1, TNF-a, adiponectin and leptin concentrations.
Conclusions/Significance: 26-wks VAL treatment markedly reduced abdominal subcutaneous adipocyte size and AT
macrophage infiltration markers, and increased ATBF in IGM subjects. The VAL-induced decrease in adipocyte size was
associated with reduced expression of macrophage infiltration markers in AT. Our findings suggest that interventions
targeting the RAS may improve AT function, thereby contributing to a reduced risk of developing cardiovascular disease
and type 2 diabetes.
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Introduction
Multiple lines of evidence suggest that increased activation of
the renin-angiotensin system (RAS) is involved in the development
of type 2 diabetes mellitus [1–4]. A meta-analysis of comparative
outcome trials has demonstrated that RAS blockade reduced the
incidence of new-onset type 2 diabetes by 22% in high-risk
subjects [5]. More recently, the prospective NAVIGATOR trial
has shown that treatment with the angiotensin (Ang) II type 1
receptor blocker (ARB) valsartan, in addition to lifestyle modifi-
cation, reduced type 2 diabetes incidence by 14% in subjects with
impaired glucose tolerance (IGT) [6]. Thus, these findings
corroborate the assertion that RAS blockade is protective against
the development of type 2 diabetes in humans.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39930The beneficial effects of RAS blockade in the prevention of type
2 diabetes have been explained by improved insulin sensitivity and
insulin secretion [1–3]. Studies that have investigated the effect of
short-term RAS blockade on insulin sensitivity, however, report
conflicting results [7], and the underlying mechanisms are not yet
fully understood. RAS components have been identified in a
variety of tissues, including adipose tissue (AT), and it has been
demonstrated that increased activation of the RAS is linked to
insulin resistance [1]. Converging evidences suggest that several
aspects of AT dysfunction, including macrophage infiltration,
inflammation and impaired AT blood flow (ATBF), contribute to
insulin resistance [8]. Thus, it is tempting to postulate that RAS
blockade may improve AT function, thereby increasing insulin
sensitivity. Indeed, RAS blockade decreased adipocyte size and
AT gene expression of inflammatory markers, and improved
glucose homeostasis in rodents [9–14]. However, it is presently
unknown whether long-term RAS blockade evokes beneficial
effects on AT function in humans.
The objective of the present study was to investigate whether
long-term RAS blockade improves AT function in subjects with
impaired glucose metabolism (IGM). We have recently conducted
a randomized placebo-controlled trial and demonstrated that 26-
wks VAL treatment improved both insulin sensitivity and glucose-
stimulated insulin secretion in subjects with IGM [15]. To
elucidate the underlying mechanisms for improved insulin
sensitivity, the present study examined the effects of 26-wks RAS
blockade on several factors associated with AT function, including
adipocyte size, ATBF, gene expression of angiogenesis/capillar-
ization, adipogenesis, lipolytic and inflammatory cell markers in
AT, and systemic inflammation.
Methods
Ethics Statement
The present study was conducted within the framework of the
PRESERVE study, a randomized double-blind, placebo-con-
trolled, parallel-group study carried out in two different centers in
The Netherlands (Maastricht (n=38), Amsterdam (n=41)) [15].
The original protocol for this trial and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocol S1. Just before the start of the trial, we decided not to
initiate the rosiglitazone arm because of the reported potential
cardiovascular risks associated with rosiglitazone [16]. The present
sub-study was performed at Maastricht University Medical
Center. All clinical investigations conformed to the standards set
by the Declaration of Helsinki, the Medical-Ethical Committee of
Maastricht University Medical Center approved the study
protocol, including the present sub-study, and subjects gave their
written informed consent before participation.
Subjects
Figure 1 describes the flow of participants through the main trial
[15]. Eligible participants were assigned to valsartan or placebo
according to a computer-generated, randomization plan (block
size, n=4). The local pharmacy (Maastricht University Medical
Center) generated the random allocation sequence and assigned
participants to interventions.
In the present sub-study, thirty-eight subjects with impaired
fasting glucose (IFG; fasting plasma glucose $6.1 and
,7.0 mmol/l or FPG $5.6 and ,7.0 mmol/l with family history
(first-degree relative) of type 2 diabetes), and/or IGT (2 h plasma
glucose concentration $7.8–11.1 mmol/l) (isolated IFG, n=19;
isolated IGT, n=9; combined IFG/IGT, n=10) were randomly
assigned to VAL (n=19) or PLB (n=19) treatment. Subjects
received 160 mg VAL or PLB once daily (q.d.) for 2 weeks.
Thereafter, the dosage was doubled to 320 mg q.d. VAL or PLB
for the subsequent 24 wks. Study medication was taken in the
evening throughout the treatment period. Before and after 26-wks
treatment, a hyperinsulinemic-euglycemic clamp, OGTT, and
postprandial study (measurement of fasting and postprandial
ATBF) were performed, and an AT biopsy was collected. All
baseline procedures were randomized and completed within 5
weeks after inclusion, with at least 1 week between measurements,
after an overnight fast. We were not able to obtain AT biopsies of
sufficient quality for mRNA expression (low RIN-value) in 6 VAL-
treated subjects, were not able to quantify adipocyte size due to
tissue damage in 7 subjects (3 PLB and 4 VAL-treated subjects),
and were unable to perform ATBF measurements in 8 subjects (5
PLB and 3 VAL-treated subjects) either before or after treatment.
One data-point for insulin sensitivity (1 VAL subject) was
considered an outlier in the statistical analysis.
Exclusion criteria were diabetes mellitus, cardiovascular disease,
cancer, lung disease, abnormal liver (alanine aminotransferase
(ALAT).35 U/l and gamma-glutamyl transferase (GGT).35 U/
l) and renal function (creatinine.110 mmol/l) tests, intentions to
lose weight or follow a hypocaloric diet and alcohol or drug abuse.
Subjects were only allowed to use statins (n=1). Subjects with a
blood pressure .140/90 mmHg at screening were treated with
5 mg amlodipine. If blood pressure .140/90 mmHg persisted,
the amlodipine dosage was increased to 10 mg, followed by
addition of hydrochlorothiazide 12.5 mg and/or carvedilol 25 mg
if needed. Individuals with a blood pressure ,140/90 mmHg
entered the study. Fourteen subjects required amlodipine (VAL
group, 6 subjects; PLB group, 8 subjects), and in seven of these
subjects hydrocholothiazide was added (VAL group, 2 subjects;
PLB group, 5 subjects) to control blood pressure.
Adipose Tissue Biopsy
An abdominal subcutaneous AT biopsy (,1 g) was collected 6–
8 cm lateral from the umbilicus under local anesthesia (2%
lidocaine) by needle biopsy after an overnight fast. AT was washed
with sterile saline and processed within 5 min. A small part of the
AT was fixed overnight in 4% paraformaldehyde and embedded
in paraffin, whereas the other part was snap frozen in liquid
nitrogen and stored at -80uC.
Adipocyte size. Histological sections (8 mm) were cut from
paraffin-embedded tissue, mounted on microscope glass slides and
dried overnight in an incubator at 37uC. Sections were stained
with haematoxylin and eosin. Digital images were captured using a
Leica DFC320 digital camera (Leica DM3000 microscope, Leica,
Rijswijk, The Netherlands) at 206 magnification. Computerized
morphometric analysis (Leica QWin V3, Cambridge, UK) of
individual adipocytes (.400 adipocytes/sample) was performed in
a blinded fashion, with a coefficient of variation ,5%.
Quantitative RT-PCR. Total RNA was extracted from AT
(,500 mg) using Trizol chloroform extraction (Invitrogen, Cergy
Pontoise, France) for measurement of gene expression of
angiogenesis/capillarization, adipogenesis, lipolytic and inflam-
matory cell markers. SYBR-Green based real-time PCRs were
performed as one-step reactions on the StepOne real-time PCR
system (Applied Biosystems, Foster City, CA). Results were
normalized to 18 S ribosomal RNA.
Western blot analysis. AT (,200 mg) was ground to fine
powder under liquid nitrogen and homogenized in 200 ml of ice-
cold buffer [17]. The homogenate was vortexed, centrifuged
(20,000 g, 30 min, 4uC), and supernatant was collected and stored
at -80uC. The protein concentration was determined by the
Bradford-based protein assay (catalog no. 500-0006; Bio-Rad).
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described previously [17]. CGI-58 was detected using a rabbit
polyclonal antibody raised against human CGI-58 (Novus
Biologicals, NB110-41576). The G0S2 antibody [18] was a kind
gift from Dr. Sander Kersten (Wageningen University, The
Netherlands).
Fasting and Postprandial ATBF
ATBF was continuously measured at baseline and for 4 h after
consumption of a standardized high-fat mixed meal (consisting of
61E% fat (35.5E% saturated fatty acids (FAs), 18.8E% monoun-
saturated FAs and 1.7E% polyunsaturated FAs), 33E% carbohy-
drate and 6E% protein, containing 2.6 MJ), as previously
described [19,20]. Briefly,
133Xe (,1 MBq) was injected para-
umbilically into the adipose tissue, approximately 10 mm deep. A
CsI crystal detector (Oakfield Instruments, Eynsham, UK) was
placed over the exact site of injection and taped firmly in place to
monitor the mono-exponential decay of radioactivity in the
adipose tissue. This c-counter probe collected continuous 20 s
readings.
Hyperinsulinemic-euglycemic Clamp
A hyperinsulinemic-euglycemic clamp was performed to assess
insulin sensitivity [21]. Briefly, a cannula was inserted into a
superficial dorsal hand vein for sampling of arterialized blood and
in an antecubital vein of the contralateral forearm for insulin
(40 mU/m
2/min, Actrapid, Novo Nordisk Farma BV, Alphen aan
den Rijn, The Netherlands) and glucose infusion. Blood glucose
concentration was measured every 5 min (EML 105, Radiometer,
Copenhagen, Denmark) and euglycemia was maintained at
5.0 mmol/l (variable 20% glucose infusion). The mean glucose
infusion rate (M-value) during steady-state (last 30 min of the
clamp) was used to assess insulin sensitivity.
Biochemical Analyses
Blood samples were collected into ice-chilled EDTA-tubes and
centrifuged at 1000 g, 4uC for 10 min. Plasma was immediately
frozen in liquid nitrogen and stored at -80uC until analysis. Plasma
glucose concentrations were determined using a hexokinase
method (Gluco-quant, Roche Diagnostics, Mannheim, Germany).
HbA1c was measured by cation exchange chromatography
(Menarini Diagnostics, Florence, Italy). Plasma insulin concentra-
tions were quantified using an immunometric assay (Advia,
Siemens Medical Solutions Diagnostics, IL). Serum monocyte
chemoattractant protein-1 (MCP-1), tumour necrosis factor-a
(TNF-a) and leptin concentrations were measured using the
Bioplex Protein Array System (Bio-Rad Laboratories, Hercules,
CA) by fluorescent conjugated monoclonal antibodies. Adiponec-
Figure 1. Enrollment flow chart.
doi:10.1371/journal.pone.0039930.g001
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Systems, Abingdon, UK).
Statistical Analysis
Baseline comparisons between treatment groups were analyzed
using Student’s unpaired t test. Treatment effects were assessed by
repeated-measures ANOVA, using time as within-subject factor
and treatment as between-subject factor, with adjustment for
gender and glucometabolic status (IFG, IGT or combined IFG/
IGT). Univariate correlations were used to examine associations
between parameters. Since adjustment for gender and glucometa-
bolic status did not affect the results, unadjusted values were used.
All variables were checked for normal distribution, and variables
with a skewed distribution were ln-transformed to satisfy
conditions of normality. Data are presented as means6SEM, or
as medians (interquartile range) in case of non-normal distribution.
Calculations were done using SPSS 15.0 for Windows (Chicago,
IL, USA). P,0.05 was considered to be statistically significant.
Results
All individuals randomized completed the present study. Subject
characteristics are summarized in Table 1. Before the start of
treatment, age, BMI, body fat percentage, waist and hip circum-
ferences, blood pressure, lipid profile, plasma glucose and insulin
concentrations, and insulin sensitivity were comparable between
subjects randomized to VAL or PLB. The study medication was
well-tolerated and no serious adverse events were reported.
Blood Pressure
At baseline, both systolic and diastolic blood pressure was
comparable between treatment groups (Table 1). VAL treatment
decreased systolic (VAL: 215.763.2 vs. PLB: 24.361.7 mmHg,
P=0.004) and diastolic (VAL: 28.762.1 vs. PLB:
22.061.4 mmHg, P=0.009) blood pressure compared with
PLB (Table 1).
Adipocyte Size
At baseline, abdominal subcutaneous adipocyte size was
comparable between treatment groups (VAL: 70.062.1 vs. PLB:
65.661.8 mm, P=0.121). VAL treatment markedly reduced mean
adipocyte size compared with PLB (P,0.001, Figure 2A), with a
shift toward a higher proportion of small adipocytes (Figure 2B).
Noteworthy, the reduction in adipocyte size was a very consistent
finding, since this was observed in all subjects treated with VAL.
AT gene expression of peroxisome proliferator-activated recep-
tor (PPAR)c (P=0.061), adipocyte fatty acid binding protein (aP2)
(P=0.016) and CCAAT/enhancer binding protein (C/EBP)a
(P=0.006), which are key regulatory factors in adipogenesis and
lipogenesis [22], were decreased after VAL treatment compared
with PLB (Table 2).
ATBF and AT Gene Expression of Capillarization and
Hypoxia Markers
Both fasting ATBF (VAL: 1.760.2 vs. PLB: 1.860.1 ml?100g
tissue
21?min
21, P=0.675) and the postprandial enhancement of
ATBF (iAUCATBF/min) after consumption of the high-fat mixed-
meal (VAL: 0.2160.11 vs. PLB: 0.3760.12 ml?100g tissue
21
min
21, P=0.349) were comparable before the start of treatment.
VAL increased both fasting (P=0.043) and postprandial
(P=0.049) ATBF compared with PLB (Figure 3A and B,
respectively). Adjustment for non-significant baseline differences
in ATBF between groups did not alter the results.
Table 1. Subject characteristics before and after 26-wks treatment with VAL or PLB.
Valsartan (n=19) Placebo (n=19)
Baseline 26 wks Baseline 26 wks P-value*
Sex (male/female) 7/12 – 11/8 – –
Age (yr) 59.461.5 – 59.261.2 – N.S.
Weight (kg) 86.263.0 86.663.3 90.264.0 90.163.9 N.S.
BMI (kg/m
2) 30.661.0 30.761.1 30.961.2 30.961.2 N.S.
Total body fat (%) 34.661.9 34.361.9 31.861.5 32.361.6 0.073
Trunk fat (%) 35.361.9 35.561.9 33.761.5 34.361.5 N.S.
Waist (cm) 101.162.4 102.863.1 104.763.1 105.362.9 N.S.
Hip (cm) 105.562.2 106.662.5 103.062.0 105.662.3 N.S.
WHR 0.9660.02
# 0.9660.02 1.0260.02 1.0060.02 N.S.
SBP (mmHg) 127.062.1 111.562.4 130.263.0 124.562.8 0.004
DBP (mmHg) 79.561.6 70.861.1 80.162.0 78.661.9 0.009
Fasting glucose (mmol/l) 6.460.1 6.260.2 6.260.1 5.960.1 N.S.
2h-glucose (mmol/l) 7.560.6 7.760.6 7.660.6 8.560.6 N.S.
Fasting insulin (pmol/l) 103.0620.6 104.0614.7 100.7610.9 100.368.9 N.S.
HbA1C (%) (mmol/mol) 6.160.1 (42.961.3) 6.060.1 (41.661.2) 6.060.1 (41.861.0) 6.060.1 (42.361.2) N.S.
M-value (mg?min
21?kg
21)3 . 4 60.4 3.660.4 3.260.4 3.160.3 N.S.
Fasting TAG (mmol/l) 1.2360.08 1.4860.10 1.3960.15 1.6960.23 N.S.
Fasting NEFA (mmol/l) 570.0643.9 520.6646.1 577.9640.2 567.5672.3 N.S.
BMI, body mass index; HbA1C, glycated haemoglobin; NEFA, non-esterified fatty acid; SBP, systolic blood pressure; DBP, diastolic blood pressure; TAG, triacylglycerol;
WHR, waist-to-hip ratio; N.S., not significant.
*VAL vs. PLB treatment assessed by repeated-measures ANOVA.
#P,0.05 vs. PLB. Values are means6SEM.
doi:10.1371/journal.pone.0039930.t001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39930Figure 2. Mean adipocyte diameter and adipocyte size distribution. VAL treatment (n=15) significantly reduced (A) adipocyte size
compared with PLB (n=16), with (B) a shift toward a higher proportion of small adipocytes. Values are means6SEM. *P,0.05,
#P,0.01,
{P,0.001
VAL vs. PLB.
doi:10.1371/journal.pone.0039930.g002
Table 2. Abdominal subcutaneous AT gene expression before and after 26-wks treatment with VAL or PLB.
Valsartan (n=19) Placebo (n=13)
Baseline 26 wks Baseline 26 wks P*
Adipogenesis
PPARc mRNA 1.25 (0.64–1.72) 0.94 (0.55–1.15) 0.83 (0.42–1.06) 1.51 (0.53–1.69) 0.061
aP2 mRNA 0.86 (0.38–1.31) 0.45 (0.27–0.62) 0.65 (0.37–0.90) 0.74 (0.39–1.07) 0.016
C/EBPa mRNA 1.12 (0.82–0.87) 0.94 (0.60–1.07) 1.13 (0.71–1.54) 1.27 (0.90–1.83) 0.006
Capillarization
VEGF mRNA 0.58 (0.41–0.94) 0.54 (0.31–0.66) 0.50 (0.23–0.76) 0.63 (0.32–0.72) 0.051
CD34 mRNA 0.78 (0.60–1.18) 0.65 (0.49–1.16) 0.73 (0.34–1.02) 1.03 (0.45–1.44) 0.037
ANG mRNA 0.58 (0.41–0.68) 0.50 (0.21–0.66) 0.39 (0.32–0.67) 0.46 (0.38–0.77) 0.028
Inflammation
CD68 mRNA 1.97 (0.80–2.52) 0.94 (0.63–1.74) 0.79 (0.64–1.58) 1.78 (0.98–2.93) 0.014
CD163 mRNA 1.21 (0.87–1.99) 0.80 (0.56–1.20) 1.00 (0.91–1.59) 1.41 (1.05–1.82) 0.023
CD206 mRNA 1.17 (0.85–1.73) 0.90 (0.53–1.45) 1.03 (0.63–1.31) 1.35 (0.81–2.38) 0.004
CD11b mRNA 1.58 (0.78–2.31) 1.54 (0.61–2.18) 1.11 (0.77–2.05) 1.94 (1.02–2.89) 0.364
CTSS mRNA 1.01 (0.48–1.37) 0.79 (0.35–1.07) 0.57 (0.40–0.82) 0.79 (0.57–1.40) 0.014
Lipolysis
ATGL mRNA 0.74 (0.37–1.11) 0.39 (0.28–0.74) 0.65 (0.48–1.04) 0.68 (0.50–1.27) 0.083
CGI-58 mRNA 0.52 (0.35–0.78) 0.34 (0.20–0.49) 0.35 (0.23–0.88) 0.52 (0.25–0.86) 0.090
HSL mRNA 2.10 (1.42–3.14) 1.60 (0.96–2.46) 3.10 (1.54–4.42) 2.48 (1.64–3.85) 0.710
G0S2 mRNA 0.87 (0.56–1.39) 0.59 (0.38–1.08) 0.78 (0.54–1.22) 0.99 (0.48–1.76) 0.092
PPARc, peroxisome proliferator-activated receptor c; aP2, adipocyte fatty acid binding protein; C/EBPa, CCAAT/enhancer binding protein a; VEGF, vascular endothelial
growth factor; ANG, angiogenin; CTSS, cathepsin S; ATGL, adipose triglyceride lipase; CGI-58, comparative gene indentification 58; G0S2, G0/G1 switch gene 2; HSL,
hormone-sensitive lipase.
*VAL vs. PLB treatment assessed by repeated-measures ANOVA. Values are medians (interquartile range).
doi:10.1371/journal.pone.0039930.t002
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(VEGF), the master regulator of vasculogenesis, angiogenesis and
remodeling of blood vessels [23], was decreased after VAL
treatment compared with PLB (P=0.051) (Table 2). In accor-
dance, VAL reduced AT gene expression of the angiogenesis and
capillarization markers CD34 (P=0.037) and angiogenin (ANG)
(P=0.028) (Table 2). VAL treatment did not affect mRNA
expression of the hypoxia marker GLUT-1 (P=0.741).
AT Chemoattraction, Macrophage Infiltration and
Inflammatory Markers
Adipocyte size was positively associated with AT gene
expression of chemoattraction, macrophage infiltration and
inflammatory markers (data not shown). VAL treatment
decreased AT gene expression of the macrophage infiltration
markers CD68 (P=0.014), CD163 (P=0.023) and CD206
(P=0.004) (Table 2). Furthermore, VAL decreased cathepsin S
(CTSS) (P=0.014) AT mRNA expression (Table 2), which may
reflect an improved inflammatory state of AT [24]. AT gene
expression of monocyte-chemoattractant protein (MCP)-1
(P=0.202), IL-6 (P=0.426), TNF-a (P=0.464) plasminogen
activator inhibitor (PAI)-1 (P=0.476) and adiponectin
(P=0.393) was not altered.
The change in adipocyte size after VAL treatment was
associated with alterations in AT gene expression of CD68
(r=0.639, P=0.010), CD11b (r=0.539, P=0.033), CD163
(r=0.514, P=0.050), CD206 (r=0.504, P=0.056), CTSS
(r=0.648, P=0.017) and TNF-a (r=0.468, P=0.091).
Systemic Inflammation
At baseline, fasting plasma MCP-1 (P=0.994), TNF-a
(P=0.243), adiponectin (P=0.595) and leptin (P=0.380) concen-
trations were comparable between groups (Figure 4A-D). VAL
treatment did not significantly alter plasma concentrations of
MCP-1 (P=0.497), TNF-a (P=0.106), adiponectin (P=0.312)
and leptin (P=0.117) compared with PLB (Figure 4A-D).
AT Expression of Lipolytic Enzymes and Co-factors
involved in Lipolysis
VAL treatment did not significantly alter AT gene expression of
the lipolytic enzyme adipose triglyceride lipase (ATGL)
(P=0.083), its activator protein comparative gene indentification
58 (CGI-58) (P=0.090), G0/G1 switch gene 2 (G0S2) (P=0.092) -
which may attenuate ATGL action [25] – and hormone-sensitive
lipase (HSL) (P=0.710) compared with PLB (Table 2).
In line, AT protein expression of ATGL (P=0.335), CGI-58
(P=0.947), G0S2 (P=0.299) and HSL (P=0.821) was not altered
after VAL treatment compared with PLB.
Insulin Sensitivity
The present study was conducted within the framework of
the PRESERVE study, in which we have recently demonstrated
that 26-wks VAL treatment significantly increased insulin
sensitivity [15]. Although the change in insulin sensitivity after
VAL treatment was of the same order of magnitude (,10%) in
the subset of subjects that was studied here (n=38) compared
with the total study population (n=79), the VAL-induced
increase in insulin sensitivity did not reach statistical significance
in the present analysis (P=0.248; Table 1). Importantly, the
present study was not powered to detect a VAL-induced change
in insulin sensitivity. Interestingly, however, treatment-induced
alterations in adipocyte size were significantly correlated with
changes in insulin sensitivity (r=20.452, P=0.012) (Figure 5).
Discussion
Recent large clinical trials have demonstrated that RAS
blockade reduces the incidence of type 2 diabetes [5,6]. We have
Figure 3. Fasting and postprandial ATBF. VAL treatment (n=16) significantly increased both (A) fasting ATBF and (B) postprandial ATBF
(P=0.049) compared with PLB (n=14). A high-fat mixed-meal (containing 2.6 MJ, consisting of 61E% fat (35.5E% saturated fatty acids (FAs), 18.8E%
monounsaturated FAs and 1.7E% polyunsaturated FAs), 33E% carbohydrate and 6E% protein) was ingested at t0 min. Values are means6SEM.
*P,0.05 VAL vs. PLB. ATBF, adipose tissue blood flow.
doi:10.1371/journal.pone.0039930.g003
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sensitivity and beta-cell function in subjects with IGM [15]. The
present study demonstrated that 26-wks VAL treatment markedly
reduced abdominal subcutaneous adipocyte size and AT macro-
phage infiltration markers, and increased ATBF in IGM subjects.
The VAL-induced decrease in adipocyte size was associated with
reduced expression of macrophage infiltration markers in AT.
We have previously shown that local administration of Ang II,
the active component of the RAS, in abdominal subcutaneous AT
decreased [19,26], whereas local infusion of the ARB losartan
increased ATBF in humans [19]. We therefore hypothesized that
long-term oral ARB treatment may increase ATBF. Indeed, the
present data showed that 26-wks VAL treatment increased both
fasting and postprandial ATBF compared with PLB. As antici-
pated, the magnitude of the ATBF increase in the present study
(,35%) was lower than that observed during local ARB
administration into AT (,55%) [19]. Previous studies from our
laboratory and others have demonstrated that both fasting ATBF
and the postprandial increase in ATBF are decreased in obese,
insulin resistant subjects [27–29], which was closely associated
with insulin resistance [27,29]. In fact, it has previously been
shown that increased ATBF improved AT lipid handling via an
enhanced triacylglycerol clearance [30] and decreased reesterifica-
tion of non-esterified fatty acids [31], thereby preventing an
excessive flux of lipids toward non-adipose tissues (ectopic fat
storage) and, as a consequence, insulin resistance [8]. Therefore,
the increased ATBF after VAL treatment may have contributed to
increased insulin sensitivity, although the lack of a significant
association between the VAL-induced increase in ATBF and
alteration in insulin sensitivity in the present study may argue
Figure 4. Circulating inflammatory markers. VAL treatment (n=17) did not significantly affect plasma concentrations of (A) MCP-1, (B) TNF-a,
(C) adiponectin and (D) leptin compared with PLB (n=19). MCP-1, monocyte chemoattractant protein-1; TNF-a, tumour necrosis factor-a.
doi:10.1371/journal.pone.0039930.g004
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markers was significantly reduced after VAL treatment, which
may reflect a lowered angiogenic response secondary to the
increase in ATBF. Recent data from our group [27] and others
[32] suggest that oxygen tension in human AT ranges from 3.2–
11.3%, which might not be low enough to activate the HIF-1a
pathway [33]. This, together with the present findings of
unchanged GLUT1 mRNA expression in AT after VAL
treatment, suggests that it is highly unlikely that modulation of
the HIF-1a pathway has contributed to the VAL-induced
improvement of AT function.
Interestingly, we found that 26-wks VAL treatment markedly
reduced mean adipocyte diameter and increased the proportion of
small adipocytes. Abdominal subcutaneous adipocyte hypertrophy
appears to be an independent marker of insulin resistance [34].
The reason for this may be that hypertrophic adipocytes have a
reduced lipid buffering capacity and show disturbances in
adipokine expression, with a shift toward a more proinflammatory
phenotype [8,27]. Thus, we speculate that VAL treatment may
have evoked beneficial changes in the adipocyte secretory profile
associated with smaller adipocytes, which in turn may have
contributed to favorable alterations in metabolism. In addition, we
found a decreased gene expression of macrophage infiltration
markers in AT after VAL treatment. Interestingly, the VAL-
induced change in adipocyte size was strongly associated with
alterations in insulin sensitivity and AT gene expression of both
M1 (CD11b) and M2 (CD163 and CD206) macrophage
infiltration markers, which underlines the importance of adipocyte
size reduction in adipose tissue function. These findings are in
agreement with previous studies in rodents, showing that ARB
treatment reduced adipocyte size and AT inflammation, and
improved glucose homeostasis [9–14]. Of note, the change in
insulin sensitivity was not a primary outcome parameter in the
present study, which may explain why the VAL-induced increase
in insulin sensitivity did not reach statistical significance, in
contrast with our recent findings in a larger group of subjects with
IGM [15].
The reduction in AT gene expression of macrophage infiltration
markers did not translate into significant alterations in circulating
MCP-1, TNFa, leptin and adiponectin concentrations in the
present study. Importantly, however, we cannot exclude that the
reduction in macrophage infiltration markers decreased the
expression and/or secretion of other adipokines that have been
linked to insulin resistance. In accordance with the present
findings, it has been shown that ARB treatment had no effects on
circulating leptin, TNF-a and adiponectin, despite increased
insulin sensitivity [35]. In contrast, other studies have demonstrat-
ed alterations in circulating adipokines after ARB treatment
[36,37]. These apparently conflicting findings may be explained
by differences in study population, since in several of these studies
patients with essential hypertension and/or increased systemic
inflammation participated.
Based on cell experiments and studies in rodents [11,13,14,38],
we hypothesized that stimulation of adipocyte differentiation may
underlie the VAL-induced decrease in adipocyte size. We found
that AT gene expression of the adipocyte differentiation marker
PPARc was significantly reduced, rather than increased, after
VAL treatment. Although this finding was surprising, it may well
be that adipocyte size was already reduced several weeks before
the end of treatment, which may in turn have down-regulated
PPARc expression, since the decrease in adipocyte size was
strongly associated with reduced PPARc expression after VAL
treatment. Unfortunately, we did not collect AT biopsies at
multiple time-points during the treatment period to confirm this.
Important processes in the regulation of adipocyte size, in
addition to adipocyte differentiation, include the storage and
release of fatty acids. In accordance with previous findings showing
increased lipid synthesis and storage in 3T3-L1 and human
adipocytes during Ang II stimulation [39], we found that VAL
treatment reduced AT gene expression of aP2 and C/EBPa,
Figure 5. Correlation between the change in adipocyte diameter and insulin sensitivity after 26-wks VAL or PLB treatment (n=30).
The decrease in adipocyte size was significantly associated with alterations in insulin sensitivity after VAL (n=14, closed circles) and PLB (n=16, open
circles) treatment (r=20.452, P=0.012).
doi:10.1371/journal.pone.0039930.g005
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[22]. These data may suggest that decreased AT lipogenesis
underlies the VAL-induced decrease in adipocyte size. Further-
more, we assessed whether VAL affects lipolysis, since previous
findings from our group indicate that Ang II exerted modest
inhibitory effects on AT lipolysis in humans [26]. However, both
AT gene and protein expression of several lipolytic enzymes were
not altered by VAL. These data indicate that it is unlikely that
increased AT lipolysis has contributed to a significant extent to the
VAL-induced decrease in adipocyte size in the present study.
However, we cannot fully exclude that lipase activity was
stimulated during the early phase of treatment.
In conclusion, we demonstrated that 26-wks VAL treatment
markedly reduced abdominal subcutaneous adipocyte size and AT
macrophage infiltration markers, and increased ATBF in IGM
subjects. The VAL-induced decrease in adipocyte size was
associated with reduced expression of macrophage infiltration
markers in AT. In other words, our data indicate that VAL
treatment was able to prevent further deterioration of AT function
in subjects with IGM. Thus, improved AT function may underlie
the increased insulin sensitivity [15] and reduced incidence of type
2 diabetes after long-term ARB treatment in subjects at high-risk
of developing this disease. Furthermore, our findings imply that
other interventions targeting the RAS may improve AT function,
thereby lowering the risk for cardiovascular disease and type 2
diabetes.
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